Alnylam Pharmaceuticals, Inc. vs International Business Machines Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.91 (market cap $29.60B), while International Business Machines Corp trades at $234.86 (market cap $224.62B). The key difference: International Business Machines Corp is far larger — about 7.6× Alnylam Pharmaceuticals, Inc.'s market cap, and International Business Machines Corp pays a 2.84% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | IBM | |
|---|---|---|
Market Cap | $29.60B | $224.62B |
Sector | Health | Technology |
52-Week High | $491.22 | $329.23 |
52-Week Low | $205.48 | $205.77 |
Enterprise Value | $27.56B | $281.76B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.84% |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
IBM trades at $233.94, down 1.0% today, as the stock navigates mixed signals. Recent earnings showed a Q2 2026 EPS miss after two consecutive beats, while revenue growth accelerated to $67.54 billion in 2025. Technical indicators show a bullish overall signal but bearish moving averages, with RSI levels suggesting overbought conditions. The company secured a $240 million AI deal with Together AI, but faces securities fraud investigations following a 25% stock drop earlier this year.
IBM presents a complex risk-reward profile with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus pointing to 10% upside to the $257.38 price target. However, ongoing legal investigations and increased capital expenditures creating negative cash flow pose significant near-term risks. The AI partnership momentum contrasts with concerns about IBM's competitive positioning in the rapidly evolving technology landscape.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →